The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer
Z Cheng, H Cui, Y Wang, J Yang, C Lin… - Oncology …, 2023 - spandidos-publications.com
Lung cancer is currently the second most common type of cancer with the second incidence
rate and the first mortality rate worldwide. Non-small cell lung cancer (NSCLC) accounts for …
rate and the first mortality rate worldwide. Non-small cell lung cancer (NSCLC) accounts for …
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
Introduction Recent years have seen significant strides in drug developmenttargeting the
EGFR/RAS/RAF signaling pathway which is critical forcell growth and proliferation. Protein …
EGFR/RAS/RAF signaling pathway which is critical forcell growth and proliferation. Protein …
Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer
The role of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC)
has been vastly studied over the last decade. This has led to the rapid development of many …
has been vastly studied over the last decade. This has led to the rapid development of many …
ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells
C Bergonzini, A Gregori, TMS Hagens… - Journal of Experimental …, 2024 - Springer
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of
cancer and the chemotherapies such as gemcitabine/nab-paclitaxel are confronted with …
cancer and the chemotherapies such as gemcitabine/nab-paclitaxel are confronted with …
[HTML][HTML] A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
A 3, 4-dihalo-2 (5 H)-furanone initiated ring-opening reaction of DABCO in the absence of a metal catalyst and additive and its application in a one-pot two-step …
HQ Wu, K Yang, XY Chen, M Arulkumar, N Wang… - Green …, 2019 - pubs.rsc.org
In the absence of metal catalysis and an additive, with ethyl acetate as a solvent at 95° C
under air atmosphere for 2 h, an eco-friendly and practical protocol for the synthesis of 4 …
under air atmosphere for 2 h, an eco-friendly and practical protocol for the synthesis of 4 …
Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: current status and future perspectives
YC Zhang, Q Zhou, YL Wu - Cancer Letters, 2019 - Elsevier
Discovery of activating mutations in epidermal growth factor receptor (EGFR) as a predictive
biomarker for first-generation EGFR tyrosine kinase inhibitors (TKIs) has initiated an era of …
biomarker for first-generation EGFR tyrosine kinase inhibitors (TKIs) has initiated an era of …